Nautilus Biotechnology PEG Ratio

Nautilus Biotechnology posts a PEG ratio of 60.42. That is above the Healthcare sector average of 2.8. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a PEG ratio near 2.8 is typical. Nautilus Biotechnology's 60.42 is higher that level. That is roughly 2060.8% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Nautilus Biotechnology's PEG ratio of 60.42 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.

Context for NAUT's PEG ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 2.8), and (3) consistency with growth and profitability. This page covers the first two; Nautilus Biotechnology's other metric pages and overview cover the third.

Judging Nautilus Biotechnology against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in PEG ratio easier to interpret. Start with 60.42 here, then scan peer and history charts to see if the gap is persistent.